PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsGene therapy hope for Parkinson's disease treatment

BioNews

Gene therapy hope for Parkinson's disease treatment

Published 9 June 2009 posted in News and appears in BioNews 343

Author

BioNews

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Gene therapy could help rescue a promising treatment for Parkinson's disease (PD) shelved over safety fears, New Scientist magazine reports. The drug, glial-derived neurotrophic factor (GDNF), was withdrawn in September 2004 - just five months after it had been approved for use in patients. The biotech company that made the treatment...

Gene therapy could help rescue a promising treatment for Parkinson's disease (PD) shelved over safety fears, New Scientist magazine reports. The drug, glial-derived neurotrophic factor (GDNF), was withdrawn in September 2004 - just five months after it had been approved for use in patients. The biotech company that made the treatment, Amgen, stopped a US trial because it feared the protein might cause brain damage. However, a new technique for delivering GDNF via gene therapy could now alleviate these concerns.


Parkinson's disease, which affects around 120,000 people in the UK, is caused by a gradual loss of cells in the area of the brain that controls movement. This results in tremors, muscle stiffness and eventual paralysis, even though the muscles themselves are unaffected. The disease is associated with a lack of dopamine, a brain communication chemical. In 2000, a group of US scientists showed that GDNF could promote the growth of dopamine-producing nerve cells in monkeys affected by a PD-like illness, alleviating their symptoms.


Patients enrolled in Amgen's trial had showed some improvement, but the company halted the experimental treatment over fears that it would cause brain damage similar to that seen in monkeys. Now, another US biotech firm called Rheogene might have come up with a solution: they have designed a gene therapy treatment that allows scientists to precisely control how much GDNF is delivered to the brain. It involves the use of a 'switch' attached to the GDNF gene that is only turned on in the presence of a chemical called diacylhydrazine, which can be given as a pill. 'When it's off, it's off', said Mark Braughler of Rheogene.


The company hopes that it can begin clinical trials with PD patients in 2008, after completing tests on rodents and monkeys. They also say that the system could potentially be used for other gene therapy treatments, by replacing the GDNF gene with a different target gene. 'These mechanisms are important kinds of things to develop', said Mark Kay, of the American Society of Gene Therapy.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
16 May 2017 • 2 minutes read

Gene may accelerate memory loss in Alzheimer's disease

by Dr Lone Hørlyck

A gene mutation may speed up memory loss and general cognitive decline in people who are at risk of developing Alzheimer’s disease...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 1 minute read

Parkinson's disease gene therapy shows promise

by BioNews

The first patient to receive experimental gene therapy treatment for Parkinson's disease is healthy, and has seen an improvement in his symptoms. Fifty-five year-old Nathan Klein, one of 12 people enrolled on a trial taking place at New-York Presbyterian Hospital, received the treatment a year ago. Doctors injected a virus...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 1 minute read

Parkinson's disease gene therapy trial begins

by BioNews

A US man affected by Parkinson's disease became the first patient to receive experimental gene therapy treatment for his illness last week. Fifty-five year-old Nathan Klein is one of 12 people enrolled on a new trial taking place at New-York Presbyterian Hospital, in which doctors will inject a therapeutic gene...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 1 minute read

Gene therapy for Parkinson's disease

by BioNews

A team of US researchers has used gene therapy to successfully reverse Parkinson's disease-like symptoms in monkeys. The scientists, based at Rush Presbyterian-St Luke's Medical Centre in Chicago, published their findings in last week's Science. 'Our study suggests a new approach to forestall disease progression by delivering potent factors with...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Potential pesticide threat to male fertility

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

27 June 2022 • 2 minutes read

UK report reveals public attitudes to fertility, genomics and embryo research

27 June 2022 • 2 minutes read

Shortage of sperm donors despite men willing to donate

27 June 2022 • 2 minutes read

North East London CCG proposes offering three funded IVF cycles

27 June 2022 • 2 minutes read

Fibrosis drugs reverse ovarian ageing in mice

27 June 2022 • 2 minutes read

Gene implicated in motor neurone diseases discovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856